Annual report pursuant to Section 13 and 15(d)

INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative)

v3.20.1
INTELLECTUAL PROPERTY LICENSING RIGHTS (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Oct. 12, 2018
Aug. 20, 2018
Dec. 31, 2019
Dec. 31, 2018
Amortization expense $ 1,464   $ 11,990  
Estimated useful lives 13 years   5 years  
Accumulated amortization     $ 11,990  
Patents $ 1,464    
Aggregate purchase price, value       $ 236,000
Aggregate purchase price, Shares       20,000
cash paid for acquisition       $ 10,000
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member]        
Amortization expense     $ 1,464  
Estimated useful lives     13 years  
Patent acquired $ 15,200      
February 14, 2019 [Member]        
Aggregate purchase price, value   $ 236,000    
Aggregate purchase price, Shares   20,000    
cash paid for acquisition   $ 10,000